… with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial … 18, 2021 to highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & … the partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr
… Results ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities, … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …
… in 2019. QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the … N.V. entered into a research collaboration to apply Axiomer ® to fibrosis targets selected by Galapagos. Positive … trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, CEO of ProQR. “We are …
… 2022 Operating and Financial Results Development of Axiomer ® RNA base editing technology platform continues … ended September 30, 2022, and provided a business update. Axiomer ® Program and Business Operations Updates Axiomer Program In August, ProQR announced the Company will …
… not proceed, our primary focus at ProQR remains on our Axiomer ® RNA editing platform,” said Daniel A. de Boer, … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called … in mind. Learn more about ProQR at www.proqr.com . About Axiomer® ProQR is pioneering a next-generation RNA base …
… Board (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the … 1/2 trial of QR-110, announcing the in vivo PoC for our Axiomer technology and the completion of the pre-clinical … programs and our novel RNA-editing technology, Axiomer ® . We are also thrilled with the spin out of Amylon …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … please contact your Chardan representative. About Axiomer ® ProQR is pioneering a next-generation RNA base …